EGFR and glioblastoma: Considerable heterogeneity was observed among IDH-wildtype tumors, of whom the majority consisted of STS and was reclassified as glioblastoma based on the presence of molecular markers such as gain of chromosome 7p and loss of 10q, amplification of epidermal growth factor receptor (EGFR) and/or TERT promoter mutations [2].